An overview of side effects and long-term experience with nomifensine from United States clinical trials.
During the clinical development of nomifensine maleate (Merital), 1319 depressed patients received nomifensine (average doses of 150 mg/day) in 4-6 week trials; treatment was continued for at least 2 months in 170 patients and at least 6 months in 53. Comparison data were provided by 593 patients who received placebo and 612 given the tricyclic antidepressant imipramine HCl (average doses of 150 mg/day). The relationship of therapeutic gain to interfering side effects (the therapeutic index) was rated by the investigators and nomifensine received a more favorable therapeutic index rating than did imipramine. Side effect information was collected at each visit. Nomifensine produced less sedating, anticholinergic, and other discomforting side effects than imipramine and was able to sustain clinical benefit with minimal side effects in patients treated up to 6 months.
D000328:Adult; D017109:Akathisia, Drug-Induced; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004244:Dizziness / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use; D007546:Isoquinolines / Q000627:therapeutic use*; D008875:Middle Aged; D009627:Nomifensine / Q000009:adverse effects / Q000627:therapeutic use*; D010043:Outcome and Process Assessment, Health Care; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012893:Sleep Wake Disorders / Q000139:chemically induced; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced; D014987:Xerostomia / Q000139:chemically induced
D007546:Isoquinolines; D010919:Placebos; D009627:Nomifensine; D007099:Imipramine